VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Metabolic vulnerabilities in CML & the impact of TKIs on glucose anaplerosis

Kevin Rattigan, PhD, University of Glasgow, Glasgow, UK, comments on the differences in metabolism between leukemic stem cells and their normal counterparts, highlighting the results of a study examinating the impact of tyrosine kinase inhibition on glucose anaplerosis, explaining how this may help developing novel treatment approaches in chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter